June 23rd 2025
A total of 13 drugs were granted recommendation for market authorization at EMA’s CHMP June 2025 meeting.
Polypeptide Multilayer Nanofilms in Drug Delivery
April 1st 2008Investigators are exploiting the tremendous structural diversity of polypeptides and their biophysical properties to develop novel drug carriers. Peptide-based materials hold out much promise for tailor-made targeting, penetration, and release of contents in a host of biological microenvironments.
Dissolvable Films: Dissolvable Films for Flexible Product Format in Drug Delivery
April 1st 2008For pediatric and geriatric patients, fast-dissolving drug-delivery systems provide an easier way to take medications and vitamins. Oral thin films have evolved to provide systemic delivery of active pharmaceutical ingredients for over-the-counter and soon, prescription drugs. The authors review the practical benefits of dissolvable films, their manufacture, and their market potential.
Challenges in the Secondary Manufacture of Encapsulated High-Potency Drugs
April 1st 2008Liquid and semisolid encapsulation using two-piece hard capsules is an ideal drug delivery approach for highly potent compounds and poorly water-soluble drugs. The authors detail the factors to reduce risk when designing and operating a facility for secondary manufacturing of highly potent drugs.
Sandoz Introduces New Follow-On Version of Recombinant Biotechnology Drug
March 20th 2008Sandoz introduced its "Omnitrope Pen 5" with liquid cartridge in the United States. The product was approved by the US Food and Drug Administration and is a new form of the first follow-on version of a recombinant biotechnology drug.
20th Anniversary Special Feature: Two decades of packaging development
March 1st 2008Twenty years ago it was commonplace for pills, tablets and capsules to come in small, plastic or even glass bottles. Syrups were a much more common galenic solution than today, and individual dosages of injectables were only offered in glass vials and ampoules.
The challenge of 21st century influenza
March 1st 2008Conventional influenza vaccines use an egg-based culture and harvest process. This is slow and inflexible compared with emerging cell culture-based approaches that respond rapidly to the influenza virus's inherent ability to 'drift' or, more dangerously, 'shift' - a critical factor that would arise in the event of a pandemic.